search
Back to results

A Transdiagnostic Course for Common Mental Health Problems in Primary Care

Primary Purpose

Depression, Anxiety

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material
Sponsored by
Karolinska Institutet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression focused on measuring Transdiagnostic, Primary care, Feasibility

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • At least 8 points on the GAD-7 or 10 points on the PHQ-9 (N=68; up to 25 subclinical participants may also take part in the study)
  • At least 18 years old

Exclusion Criteria:

  • At least one severe mental health problem such as suicidal ideation, a bipolar disorder, or psychosis
  • Non-stable antidepressant medication (dosage changed during the past 6 weeks)
  • Planned absence for 2 weeks or more of the intended treatment period

Sites / Locations

  • Liljeholmen primary care clinic
  • Karolinska Institutet

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Large-group transdiagnostic course

Arm Description

6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing

Outcomes

Primary Outcome Measures

Satisfaction with treatment as indicated by a mean Client Satisfaction Questionnaire (CSQ-8) score of at least 22
Theoretical range: 8-32, higher score indicates higher satisfaction. This sum score is based on 8 items, each scored 1-4. The original preregistered range of 7-28 was an erratum.

Secondary Outcome Measures

Adherence operationalized as the average number of completed sessions
Session attendance registered once each week by a clinician during the treatment period
At least 1/3 patients reporting a clinically significant improvement in symptoms of depression
Dichotomous outcome (Jacobson & Truax, 1991) based on the Patient Health Questionnaire 9 (PHQ-9, theoretical range: 0-27, higher score indicates more symptoms of depression)
At least 1/3 patients reporting a clinically significant improvement in symptoms of general anxiety
Dichotomous outcome (Jacobson & Truax, 1991) based on the GAD-7 (theoretical range: 0-21, higher score indicates more general anxiety)
Change in lifestyle behaviors
Number of adverse events
Weekly question: "Since the last assessment, have you experienced any adverse event, side effect, or unwanted effect of your participation in this study?"
Proportion of patients in need of additional treatment
Clinical interview
Average change in symptoms of depression
Patient Health Questionnaire 9 (PHQ-9, theoretical range: 0-27, higher score indicates more symptoms of depression)
Average change in general anxiety
GAD-7 (theoretical range: 0-21, higher score indicates more general anxiety)
Average change in perceived stress
Perceived Stress Scale, 10-item version (PSS-10, theoretical range: 0-40, higher score indicates more perceived stress)
Average change in disability
World Health Organization Disability Assessment Schedule 2.0 (WHODAS-2, theoretical range: 0-100, higher score indicates more disability)

Full Information

First Posted
August 10, 2020
Last Updated
March 28, 2022
Sponsor
Karolinska Institutet
Collaborators
Region Stockholm
search

1. Study Identification

Unique Protocol Identification Number
NCT04522713
Brief Title
A Transdiagnostic Course for Common Mental Health Problems in Primary Care
Official Title
Single-Arm Feasibility Study of a Transdiagnostic Course for Common Mental Health Problems in Primary Care
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
December 3, 2021 (Actual)
Study Completion Date
December 3, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
Collaborators
Region Stockholm

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study investigates the feasibility of a transdiagnostic course that is intended to work for a large variety of patient groups with clinically significant depression or anxiety in primary care. This is a prospective single-group study where 68 adults with clinically significant symptoms of depression or general anxiety, and up to 25 adults with subclinical symptoms, attend up to 6 weekly structured large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing. If necessary, due to the covid-19 pandemic, the course will be held online.
Detailed Description
Background: Depression and the common anxiety disorders are highly prevalent and associated with disability and reduced quality of life. There is reason to believe that the majority of these patients are found in primary care. Official Swedish guidelines dictate that primary care clinics are responsible for treating mild to moderate cases, but access to treatment is limited. Transdiagnostic psychological interventions have been found to be efficacious for anxiety and mood disorders, and require a relatively rudimentary pre-treatment assessment. A large-group transdiagnostic course based on cognitive-behavioral principles may constitute an effective use of limited resources to improve access to treatment, and offer a sufficiently effective intervention, for most primary care patients with mild to moderate mental health problems. Aim: To investigate the feasibility and preliminary efficacy of a large-group transdiagnostic intervention for depression and clinically significant anxiety in Swedish primary care. Design: This is a prospective single-group feasibility study where 68 adults with clinically significant symptoms of depression or anxiety, and up to 25 adults with subclinical symptoms, are recruited from Liljeholmen primary care clinic, Stockholm, and offered 6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing. If necessary, due to the covid-19 pandemic, the course will be held online. The primary outcome is patient satisfaction. Secondary outcomes include within-group effects on psychiatric symptoms (response rates), adherence rates, need for additional treatment, and adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression, Anxiety
Keywords
Transdiagnostic, Primary care, Feasibility

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective single-group cohort study
Masking
None (Open Label)
Masking Description
Psychological intervention, self-report outcomes
Allocation
N/A
Enrollment
91 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Large-group transdiagnostic course
Arm Type
Experimental
Arm Description
6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
Intervention Type
Behavioral
Intervention Name(s)
Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material
Intervention Description
Primarily standard cognitive-behavioral strategies to reduce common psychiatric symptoms
Primary Outcome Measure Information:
Title
Satisfaction with treatment as indicated by a mean Client Satisfaction Questionnaire (CSQ-8) score of at least 22
Description
Theoretical range: 8-32, higher score indicates higher satisfaction. This sum score is based on 8 items, each scored 1-4. The original preregistered range of 7-28 was an erratum.
Time Frame
Post-treatment assessment (immediately after treatment, completed within 45 days)
Secondary Outcome Measure Information:
Title
Adherence operationalized as the average number of completed sessions
Description
Session attendance registered once each week by a clinician during the treatment period
Time Frame
From week 1 to week 6
Title
At least 1/3 patients reporting a clinically significant improvement in symptoms of depression
Description
Dichotomous outcome (Jacobson & Truax, 1991) based on the Patient Health Questionnaire 9 (PHQ-9, theoretical range: 0-27, higher score indicates more symptoms of depression)
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Title
At least 1/3 patients reporting a clinically significant improvement in symptoms of general anxiety
Description
Dichotomous outcome (Jacobson & Truax, 1991) based on the GAD-7 (theoretical range: 0-21, higher score indicates more general anxiety)
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Title
Change in lifestyle behaviors
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Title
Number of adverse events
Description
Weekly question: "Since the last assessment, have you experienced any adverse event, side effect, or unwanted effect of your participation in this study?"
Time Frame
From week 1 to week 6
Title
Proportion of patients in need of additional treatment
Description
Clinical interview
Time Frame
Post-treatment assessment (within 45 days after treatment)
Title
Average change in symptoms of depression
Description
Patient Health Questionnaire 9 (PHQ-9, theoretical range: 0-27, higher score indicates more symptoms of depression)
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Title
Average change in general anxiety
Description
GAD-7 (theoretical range: 0-21, higher score indicates more general anxiety)
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Title
Average change in perceived stress
Description
Perceived Stress Scale, 10-item version (PSS-10, theoretical range: 0-40, higher score indicates more perceived stress)
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)
Title
Average change in disability
Description
World Health Organization Disability Assessment Schedule 2.0 (WHODAS-2, theoretical range: 0-100, higher score indicates more disability)
Time Frame
Pre-treatment assessment (within 2 weeks before treatment) to post-treatment assessment (immediately after treatment, completed within 45 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 8 points on the GAD-7 or 10 points on the PHQ-9 (N=68; up to 25 subclinical participants may also take part in the study) At least 18 years old Exclusion Criteria: At least one severe mental health problem such as suicidal ideation, a bipolar disorder, or psychosis Non-stable antidepressant medication (dosage changed during the past 6 weeks) Planned absence for 2 weeks or more of the intended treatment period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erland Axelsson, PhD
Organizational Affiliation
Karolinska Institutet
Official's Role
Principal Investigator
Facility Information:
Facility Name
Liljeholmen primary care clinic
City
Stockholm
ZIP/Postal Code
11763
Country
Sweden
Facility Name
Karolinska Institutet
City
Stockholm
ZIP/Postal Code
17165
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
We are willing to consider reasonable requests for individual participant data (IPD) and to consult the responsible parties accordingly. However, we do not expect to be granted permission to share IPD as long as, under Swedish and European Union (EU) data protection and privacy legislation, the IPD constitutes personal data meaning that it is possible to, using the study database, link the IPD to an identifiable living natural person.

Learn more about this trial

A Transdiagnostic Course for Common Mental Health Problems in Primary Care

We'll reach out to this number within 24 hrs